Close Menu

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive decision recommending approval for pembrolizumab (Merck's Keytruda) alone and in combination with chemotherapy for PD-L1 positive, advanced head and neck cancer patients.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.